The efficacy of NAC, especially in terms of the pCR, is currently acknowledged as an indicator of good outcomes in patients with TNBC and HER2-enriched breast cancer, which have high immune activity [3, 33, 34]. This evidence concerns the gene ERBB2 and breast carcinoma.